Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Apixaban for the Prevention of Venous Thromboembolism in High-Risk Ambulatory Cancer Patients: A Randomized Placebo-Controlled, Double-Blind Clinical Trial

NCT02048865 is registered in ClinicalTrials.gov with Ottawa Hospital Research Institute as lead sponsor.

NCT NCT02048865
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02048865 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Apixaban for the Prevention of Venous Thromboembolism in High-Risk Ambulatory Cancer Patients: A Randomized Placebo-Controlled, Double-Blind Clinical Trial
Lead sponsor
Ottawa Hospital Research Institute
Phase
Phase 2
Overall status
Completed
Start date
March 24, 2014
Completion date
October 19, 2018
Enrollment
575 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, venous thromboembolism